IRB #

STUDY00016963

Title

A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with MLL gene rearrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)

Principal Investigator

Uma Borate

Study Purpose

The purpose of this study is to determine the safety and tolerability of the experimental drug, entospletinib (ENTO, GS-9973), alone and in combination with Azacitidine (Aza, Vidaza).

Medical Condition(s)

Acute Myeloid Leukemia (AML)

Eligibility Criteria

-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-MLL gene rearrangement

Age Range

60 - n/a

Healthy Volunteers Needed

No

Duration of Participation

Study participation may include up to 5 years of study drug treatment and 30 days after you stop taking the study drug.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc

Supported by: Gilead Pharmaceuticals

Recruitment End

01/01/2037

Compensation Provided

No


Go Back